Notice: AIChE Customer Service telephone lines have been temporarily impacted by Tropical Storm Isaias. Most calls will reach a representative, however, if you have an issue please email email@example.com and we will respond as soon as possible. We apologize for any inconvenience.
Dr. Curtis J. Henry is Assistant Professor in the Department of Pediatrics at Emory University School of Medicine and a member of the Winship Cancer Center. Dr. Henry also serves on the Cancer Biology Program Executive Committee as Chair of Faculty Recruitment and was recently appointed to membership on the Graduate Division of Biological and Biomedical Sciences Task Force which is charged to improve performance, efficiency, and diversity at Emory University.
Dr. Henry received his undergraduate degrees in Molecular Biology and Chemistry from Florida Agricultural and Mechanical University (2003), follow by his doctorate degree in Immunology from Wake Forest University School of Medicine (2008). Dr. Henry then ventured west to the University of Colorado Anschutz Medical Campus where he conducted his postdoctoral fellowship (2008-2012) followed by a promotion to Research Instructor (2012-2016). While in Colorado, Dr. Henry was also an Adjunct Professor in the Department of Biology at Regis University (2009-2012).
During his career, Dr. Henry has received several prestigious grants including an NCI-funded K01, the UNCF-Merck Postdoctoral Fellowship, an American Cancer Society Junior Faculty Achievement Award, an Aflac Pilot Grant, and recently the Mark Foundation for Cancer Research ASPIRE Award. Dr. Henry has also been listed as the first or senior author on numerous manuscripts published in highly-cited journals such as Cancer Research, the Proceedings of the National Academy of Sciences of the United States of America (PNAS), and the Journal of Clinical Investigation (JCI).
Research conducted in the Henry laboratory focuses on understanding how aging and obesity promote leukemia development with the goal of improving the efficacy of chemo- and immune-based therapies in these demographics.